Skip to the main content

Review article

HISTRELIN ACETATE – THE FIRST ONCE YEARLY LHRH AGONIST

Silvio Altarac


Full text: croatian pdf 117 Kb

downloads: 677

cite


Abstract

Long-acting synthetic luteinising hormone-releasing hormone agonists have become the mainstay for androgen-deprivation therapy, because they avoid the physical and psychological discomfort associated with orchidectomy and lack the potential cardiotoxicity associated with estrogens such as diethylstilbestrol. Currently available luteinising hormone-releasing hormone agonist analogues include leuprolide, goserelin, triptorelin, degarelix and buserelin were administered as either intramuscular or subcutaneous depot injections on a 1, 2, 3 or 6 months basis. Histrelin acetate is the first long-acting luteinising hormone-releasing hormone agonist available as a once-yearly subcutaneous implant.

Keywords

Gonadotropin-releasing hormone – analogs and dirivatives, therapeutic use, administration and dosage; Antineoplastic agents, hormonal – therapeutic use, administration and dosage; Prostatic neoplasms – therapeutic use, pathology; Androgen antagonists – therapeutic use; Testosterone – blood, antagonists and inhibitors; Drug implants

Hrčak ID:

171849

URI

https://hrcak.srce.hr/171849

Publication date:

31.10.2011.

Article data in other languages: croatian

Visits: 2.007 *